Welcome to our dedicated page for DEFENCE THERAPEUTICS A news (Ticker: DTCFF), a resource for investors and traders seeking the latest updates and insights on DEFENCE THERAPEUTICS A stock.
Defence Therapeutics Inc. (symbol: DTCFF) is a Canadian biopharmaceutical company specializing in immune-oncology therapeutics and drug delivery technologies. The company recently announced the successful development of its second-generation ARMTM anti-cancer vaccine, ARM-002TM, which has shown therapeutic effectiveness against pre-established melanoma when combined with an anti-PD-1 immune-checkpoint inhibitor. Defence's unique approach involves the use of reprogrammed mesenchymal stromal cells and AccuTOX® to induce potent antigen presentation for enhanced immune response. The ARM-002TM vaccine is highly versatile and adaptable, being tested on
News
Rhea-AI Summary
Defence Therapeutics Inc. announces an amendment to its financing, conducting a non-brokered private placement of up to $2,250,000. The company will use the net proceeds to advance its preclinical and clinical programs, including the Phase I clinical trial of Defence's AccuTOX administered intratumorally in patients with stage IIIB to IV melanoma, and for general working capital.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Defence Therapeutics Inc. announces a non-brokered private placement of up to $2,790,000 to advance its preclinical and clinical programs, including the Phase I clinical trial of Defence's AccuTOX®. The company's common shares have been upgraded to OTCQB, and are now trading under the symbol 'DTCFF'.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Defence Therapeutics Inc. (DTC) successfully tested a new formulation of its ACCUM-002TM Dimer CDCA-SV40, known as AccuTOX®, for lung-established tumors. The drug demonstrated enhanced therapeutic properties and broader application in cancer therapeutics, with successful preclinical studies and FDA clearance to begin a Phase I trial in patients with melanoma. The global cancer therapeutics market size is expected to reach US$393.61 billion by 2032, presenting significant growth opportunities for the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Defence Therapeutics Inc. (CSE: DTC) (OTC Pink: DTCFF) (FSE: DTC) has received clearance from the U.S. FDA for its Phase I clinical trial of ACCUM-002TM Dimer CDCA-SV40, also known as AccuTOX®, as an injectable anticancer molecule for the treatment of solid cancer tumors. This marks a significant milestone for Defence in the immune-oncology field, positioning AccuTOX® as the company's flagship asset in the anti-cancer therapeutics field. The approval reflects the company's commitment to addressing unmet clinical needs and becoming a global leader in innovative anti-cancer therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Defence Therapeutics Inc. (CSE: DTC) (OTC Pink: DTCFF) (FSE: DTC) is pleased to announce the successful submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its ACCUM-002TM Dimer CDCA-SV40, AccuTOX®, an injectable anticancer molecule. The IND application includes preclinical animal testing data, pharmacology, pharmacokinetics, and toxicology studies, and details of drug substance and product manufacturing. The company aims to advance AccuTOX® into a Phase I clinical trial by Q1-Q2 2024. The primary objective of the upcoming trial is to identify the best therapeutic dosing range for co-administration with Opdulag®, a BMS product, in treating patients with solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.42%
Tags
-
Rhea-AI Summary
Defence Therapeutics Inc., a Canadian biopharmaceutical company, has received a Notice of allowance for its Canadian patent application. The patent covers key vaccine platform technologies that enhance the immunogenicity of protein subunit vaccines, potentially improving their efficacy and lowering antigen dose required. The company already has a counterpart US patent. Defence intends to leverage these patents to secure broad patent protection in other markets and explore licensing and partnering opportunities. The global oncology market is predicted to be worth around $536.01 billion by 2029.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.02%
Tags
Rhea-AI Summary
Defence Therapeutics announces discovery of novel function for AccuTOX® in cancer vaccine engineering
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Defence Therapeutics announces advancements in AccuTOXTM against cancer and its potential as a future treatment in immune-oncology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.46%
Tags
-
Rhea-AI Summary
Defence Therapeutics announces successful study on AccuTOXTM-chitosan encapsulated formulation
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.43%
Tags
Rhea-AI Summary
Defence Therapeutics announces publication of peer-reviewed study on anticancer properties of its product Accum®
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.53%
Tags
FAQ
What is the current stock price of DEFENCE THERAPEUTICS A (DTCFF)?
The current stock price of DEFENCE THERAPEUTICS A (DTCFF) is $0.2732 as of December 17, 2024.
What is the market cap of DEFENCE THERAPEUTICS A (DTCFF)?
The market cap of DEFENCE THERAPEUTICS A (DTCFF) is approximately 19.7M.
DEFENCE THERAPEUTICS A